Carfilzomib

Overview

Carfilzomib is a protein active pharmaceutical ingredient (ChEMBL CHEMBL451887).

API suppliers (5)

Suppliers of Carfilzomib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• CHONGQING CARELIFE PHARMACEUTICAL CO LTDChina2 active DMF
• Laurus Labs LimitedIndia1 active DMF
• SEACROSS PHARMA USA INC
• FRESENIUS KABI ONCOLOGY LTD
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD

Patent & exclusivity (US)

Per the FDA Orange Book (4 approved US products), the latest listed US patent on Carfilzomib expires 26 Aug 2033 and exclusivity 22 Nov 2028. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

(2S)-4-methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide

Canonical SMILES

CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

InChIKey

BLMPQMFVWMYDKT-NZTKNTHTSA-N